Literature DB >> 26850820

Ensemble-Based Virtual Screening and Experimental Validation of Inhibitors Targeting a Novel Site of Human DNMT1.

Manali Joshi1, Shriram N Rajpathak2, Santosh C Narwade2, Deepti Deobagkar1,2.   

Abstract

Human DNA methyltransferase1 (hDNMT1) is responsible for preserving DNA methylation patterns that play important regulatory roles in differentiation and development. Misregulation of DNA methylation has thus been linked to many syndromes, life style diseases, and cancers. Developing specific inhibitors of hDNMT1 is an important challenge in the area since the currently targeted cofactor and substrate binding site share structural features with various proteins. In this work, we generated a structural model of the active form of hDNMT1 and identified that the 5-methylcytosine (5-mC) binding site of the hDNMT1 is structurally unique to the protein. This site has been previously demonstrated to be critical for methylation activity. We further performed multiple nanosecond time scale atomistic molecular dynamics simulations of the structural model followed by virtual screening of the Asinex database to identify inhibitors targeting the 5-mC site. Two compounds were discovered that inhibited hDNMT1 in vitro, one of which also showed inhibition in vivo corroborating the screening procedure. This study thus identifies and attempts to validate for the first time a unique site of hDNMT1 that could be harnessed for rationally designing highly selective and potent hypomethylating agents.
© 2016 John Wiley & Sons A/S.

Entities:  

Keywords:  DNA methylation; DNA methyltransferase1; epigenetics; human DNA methyltransferase1; inhibitors; molecular dynamics; virtual screening

Mesh:

Substances:

Year:  2016        PMID: 26850820     DOI: 10.1111/cbdd.12741

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  4 in total

1.  Ensemble-based virtual screening: identification of a potential allosteric inhibitor of Bcr-Abl.

Authors:  Vivek Kumar Singh; Mohane Selvaraj Coumar
Journal:  J Mol Model       Date:  2017-07-01       Impact factor: 1.810

Review 2.  Epigenetics with special reference to the human X chromosome inactivation and the enigma of Drosophila DNA methylation.

Authors:  Deepti Deobagkar
Journal:  J Genet       Date:  2018-06       Impact factor: 1.166

3.  Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.

Authors:  Melissa B Pappalardi; Kathryn Keenan; Mark Cockerill; Wendy A Kellner; Alexandra Stowell; Christian Sherk; Kristen Wong; Sarath Pathuri; Jacques Briand; Michael Steidel; Philip Chapman; Arthur Groy; Ashley K Wiseman; Charles F McHugh; Nino Campobasso; Alan P Graves; Emma Fairweather; Thilo Werner; Ali Raoof; Roger J Butlin; Lourdes Rueda; John R Horton; David T Fosbenner; Cunyu Zhang; Jessica L Handler; Morris Muliaditan; Makda Mebrahtu; Jon-Paul Jaworski; Dean E McNulty; Charlotte Burt; H Christian Eberl; Amy N Taylor; Thau Ho; Susan Merrihew; Shawn W Foley; Anna Rutkowska; Mei Li; Stuart P Romeril; Kristin Goldberg; Xing Zhang; Christopher S Kershaw; Marcus Bantscheff; Anthony J Jurewicz; Elisabeth Minthorn; Paola Grandi; Mehul Patel; Andrew B Benowitz; Helai P Mohammad; Aidan G Gilmartin; Rab K Prinjha; Donald Ogilvie; Christopher Carpenter; Dirk Heerding; Stephen B Baylin; Peter A Jones; Xiaodong Cheng; Bryan W King; Juan I Luengo; Allan M Jordan; Ian Waddell; Ryan G Kruger; Michael T McCabe
Journal:  Nat Cancer       Date:  2021-09-27

4.  Expanding the Structural Diversity of DNA Methyltransferase Inhibitors.

Authors:  K Eurídice Juárez-Mercado; Fernando D Prieto-Martínez; Norberto Sánchez-Cruz; Andrea Peña-Castillo; Diego Prada-Gracia; José L Medina-Franco
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.